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Abstract Gastrointestinal stromal tumours (GISTs) are defined as a group of C-KIT
positive mesenchymal tumours of the gastrointestinal tract. Although they may
arise throughout the gut, the commonest sites are stomach and small intestine.
Over 80% of metastases are to the liver and omentum. Targeted therapy (imatinib)
can inhibit C-KIT and thereby aberrant tumoural proliferation. Imatinib may induce
shrinkage of lesions and cystic change. Such physical changes often correspond with
reduced metabolic activity demonstrated by 18-FDGPET scans. These changes may
enable metastatectomy reducing tumour pain and the risk of haemorrhage and
rupture in the short term. In the long term, resection may lessen the risk of
recurrence by removing potentially resistant clones. The precise role of palliative
resection for GIST metastases on imatinib remains unclear. Imatinib has changed
the natural history of metastatic GISTs, with increased survival times. Surgery
remains an important management strategy in the metastatic setting because
complete pathological responses are rare with imatinib. Surgery is likely to provide
the best palliation, greatest reduction in tumour burden and eliminate resistant
clones. A multidisciplinary team approach with expertise concentrated in a few
centres specialising in the management of these rare tumours is vital to the
successful outcome. Future issues regarding the management of differential
response of the metastases to imatinib are highlighted. With the emergence of
techniques enabling identification of the precise mutational status of the C-KIT
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Gastrointestinal stromal tumours (GISTs) are rare
tumours and account for 0.1e0.3% of all gastroin-
testinal cancers and 5% of all soft tissue sarcomas.1
GISTs predominantly occur in middle aged and
older patients (fifth to seventh decades) with no
significant difference in the sex incidence.2 They
are the most prevalent mesenchymal tumours of
the gastrointestinal tract, occurring throughout
the gut. The most common sites are stomach
(60%) and small intestine (20e30%), but they can
also arise from the large bowel and rectum
(10%).3,4 Ten per cent of patients present with
metastatic disease. The most frequent metastatic
sites are liver (65%) and omentum (21%); in over
50%, liver is the sole site of spread (Figs. 1 and 2).
Lymph node (6%), bone (6%) and lung metastases
(2%) are uncommon at presentation.5
The term GIST was coined by Mazur and Clark.6
Recent advances in molecular research have en-
abled the differentiation of GISTs from smooth
muscle tumours such as leiomyoma and leiomyo-
sarcoma. This distinction is important due to the
availability of targeted therapy for GISTs: Imatinib
mesylate (Glivec). Imatinib inhibits the C-KIT
tyrosine kinase and other kinases. GISTs are now
defined as a group of C-KIT tyrosine kinase re-
ceptor (CD117) positive mesenchymal tumours of
the gastrointestinal tract (Fig. 3). Ninety per cent
of GISTs express the mutated form of the C-KIT
Figure 1 Transaxial CT images showing liver metasta-
ses from a primary gastric GIST resected 2 years
previously.proto-oncogene. This mutation results in constitu-
tive activation of the C-KIT tyrosine kinase re-
ceptor and signal transduction pathway, causing
unregulated cell growth.7,8 This is the crucial
event in their pathogenesis. It is now thought that
these tumours may originate from the interstitial
cells of Cajal, the pacemaker cells of the gastro-
intestinal tract.9,10
Role of surgery in the management of
metastatic GISTs
Surgery remains the treatment of choice for primary
GISTs. All primary GISTs should be approached with
the aim of performing a complete en bloc (R0)
resection (Fig. 4).11,12 The 5 year survival rate in
patients with resected primary GISTs ranges from
48% to 65% in published series.13e15 In the MSKCC
series 40% of patients relapsed after a median
follow up of 24 months, mostly with metastatic
disease.5 Imatinib is the only effective treatment
available at present for patients with metastatic
GISTs. The overall response is reported to be as high
as 80% and the median duration of response is in
excess of 24 months.16e18 Imatinib is given orally
400 mg once daily until progression. At present
multi-slice CT is considered to be the imaging
Figure 2 Transaxial CT images showing multiple
omental metastases from a primary gastric GIST
resected 6 years previously.
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imaging may become the standard for the future,
with the wider availability of scanners. A proposed
algorithm for the management of metastatic GISTs
is shown in Fig. 5.
At present, the role of palliative resection in
patients with metastatic GISTs on imatinib is
unclear. In the pre-imatinib era, survival following
surgical resection for recurrent disease was poor,
with a median survival of less than 16 months.5 In
the imatinib era, the median survival of patients
with metastatic GISTs has improved to beyond 24
months. Imatinib may be able to downsize the
metastatic lesion(s) to enable resection of pre-
viously unresectable disease. Such tumour shrink-
age may allow a less radical resection, thereby
lessening surgical morbidity. Following imatinib
Figure 4 En bloc resection of a primary gastric GIST
(removal of the stomach, spleen and omentum) to
achieve R0 resection.
Figure 3 Primary gastric GIST: immunostaining for KIT
(CD 117). Note the strongly positive staining tumour cells
(brown colouration).treatment, cystic change in metastatic GISTs is
a common imaging finding with or without any
reduction in the size of the tumours19,20 (Fig. 6).
Following a period of imatinib administration,
18-FDGPET study can be used to confirm that the
metastatic lesions are metabolically inactive and
there is no other active disease elsewhere (Fig. 7).
These imaging findings may make surgical resec-
tion technically feasible. In the short term, oper-
ative resection eliminates tumour pain and
potential risk of rupture and haemorrhage. In the
long term, resection may lessen the risk of tumour
recurrence through the emergence of resistant
clones. Although imatinib may facilitate resection
by reducing the volume and vascularity of meta-
stases, in some instances the tumours may undergo
myxoid and/or hyaline change which may make
their resection more technically demanding.21
Histopathological analysis of resected speci-
mens may reveal residual active tumour or hyali-
nised, myxoid areas with necrosis (Fig. 8). In
general, the cystic changes on CT imaging and
the hypometabolic areas on 18-FDGPET correspond
to necrotic areas in the tumour. Pathological
complete response with absence of CD117 positiv-
ity has been noted in some resected tumours post-
imatinib therapy22 (Fig. 9).
Close liaison between the surgeon, oncologist
and radiologist is vital to optimize the timing of
resection. After stopping imatinib, resection
should be undertaken promptly. Rapid progression
of metastatic GIST, accompanied by a marked
clinical deterioration, has been noted after a long
interval between cessation and surgery.23 Hepatic
resection and peritoneal/omental debulking are
the commonest procedures performed for meta-
static GIST. It is the predominant pattern of
metastatic spread to the liver and omentum that
enables multiple surgical resections to be under-
taken without significant morbidity, should these
be necessary. At operation, every effort should be
made to remove metastatic lesions intact. Careful
dissection should be undertaken to minimise the
risk of cystic rupture in view of the changes
induced by imatinib therapy. There had been
concern that targeted therapy might impair wound
healing post-operatively. No increased risk of post-
operative complications in these patients has been
reported. Imatinib can be safely discontinued
a day before surgery and recommenced within
two weeks after surgery with no adverse effects on
wound healing.21
Experience from the MD Anderson Cancer Cen-
tre suggests that a proportion of patients with
metastatic GISTs who are on imatinib may benefit
from surgical resection. In that series, 16/17
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Advisory board UK11).patients treated with imatinib underwent com-
plete surgical resection of their disease and two
patients had a pathological complete response at
surgery. The majority of patients (11/17) had
a partial pathological response to imatinib, with
variable amounts of viable tumour still present
after therapy, indicating that surgery remains an
important part of the treatment for patients with c
kit positive GISTs.22 A German group has reported
its experience of post-imatinib resection in 11
patients. R0 resection was achieved in 10 patients
with one patient achieving a pathological com-
plete response. Hepatic metastatectomy was per-
formed in six patients and in five patients
peritoneal metastases were resected. All patients
were alive with a median follow up of 45.9
months.24 In another series, 3/35 patients with
liver metastases treated with imatinib hadcomplete resection of the hepatic metastases.25
Successful resection of initially inoperable liver
metastases from a gastric GIST following imatinib
treatment was described in a 25 year old woman in
2003.26 Other groups have attempted to combine
hepatic resections with microwave coagulation or
chemoembolization and believe that aggressive
surgery may have an impact on survival.27 Multiple
hepatic resections for recurrent metastases from
GISTs have also been reported.28
A particular subset of patients can be defined by
the differential response of their GIST metastases
to imatinib. Some lesions respond, while others
remain stable or show progression. Accordingly,
18-FDGPET imaging often shows varying uptake
between the lesions. There is currently discussion
among GIST specialists as to which lesions should
be resected in patients on imatinib. Pain, rupture
210 G. Barnes et al.and haemorrhage may be indications for resection
in both 18-FDGPET hot and 18-FDGPET cold lesions.
Another rationale exists for resecting 18-FDGPET hot
lesions early; they are likely to possess mutations
that may have conferred resistance to imatinib.
Here, surgery aims to eliminate resistant clonal
proliferation, whilst allowing continued exposure
to imatinib in the responding 18-FDGPET cold le-
sions. This approach may be useful in a small
minority of patients with metastatic GISTs who
remain fit candidates for surgery and whose lesions
remain technically respectable.12
A proportion of patients progress while on
imatinib, presumably as a result of innate or
acquired resistance. This is thought to be due to
unfavourable mutations which make the tumour
less responsive to imatinib.29,30 In the future,
elucidating the precise mutational status of C-KIT
may have an influence on the imatinib/surgery
sequencing in patients with metastatic GISTs. It
Figure 6 Transaxial CT images showing a large right
lobe hepatic GIST metastasis, and smaller splenic lesion.
(a) At diagnosis of metastases 3 years after resection of
a primary gastric GIST. (b) After 9 months of imatinib
therapy: note the characteristic cystic appearance
induced by imatinib.may make sense to optimize cytoreduction with
imatinib first and then consider surgical resection
in patients with favourable mutational status. On
the contrary, patients with unfavourable muta-
tions may benefit from early surgical intervention.
These approaches remain experimental at present
but may become incorporated into the manage-
ment algorithm in future.21
Figure 7 Coronal 18-FDGPET image showing a hepatic
GIST metastasis after 12 months on imatinib. The lesion
is metabolically inactive.
Figure 8 Hepatic metastasis: high power haematox-
ylin & eosin staining of resected specimen post-imatinib
therapy. Liver tissue separates nodules of hypocellular
tumour containing bland spindle cells (arrows).
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The role of surgery in metastatic GISTs remains
unclear. Imatinib has changed the natural history
of metastatic GISTs. In a proportion of patients
with initially unresectable disease, imatinib
treatment may now enable surgical resection.
We believe that surgical resection should be
explored at every stage in the natural history of
metastatic GISTs. Close liaison between oncology,
radiology and the surgical teams is essential.
Each case should undergo careful ongoing review
by a multidisciplinary team which has the expe-
rience of managing these rare tumours. Surgical
resection, when feasible, is likely to provide the
best palliation, greatest reduction in tumour
burden and may potentially eliminate resistant
clones. It cannot be overemphasized that difficult
decisions regarding surgical intervention need to
be made on a case by case basis, taking into
account the patients’ wishes and their physiolog-
ical ability to withstand surgical trauma with
palliative goals.
The question for the GIST oncological and
surgical community is how to integrate surgery
in patients with unresectable/metastatic GISTs,
with targeted therapy. When does one recom-
mend surgery in patients with unresectable or
metastatic GISTs? Does surgical debulking pre-
ceded by targeted therapy at any stage improve
the overall survival? Should one continue imatinib
after complete resection of metastatic disease?
These questions can only be answered by pro-
spective international multicentre randomized
controlled studies, a number of which are already
in progress.
Figure 9 Hepatic metastasis: immunostaining for KIT
(CD117). Sparsely positive tumoural cells following
imatinib therapy.References
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